T3D Therapeutics Achieves Key Milestone: Announcing Final Patient Enrolled in a Phase 2a Trial of T3D-959 for Treatment of Mild to Moderate Alzheimer’s Disease

T3D Therapeutics, Inc. has achieved a significant clinical trial milestone in its Phase 2a feasibility study in mild to moderate Alzheimer’s disease patients with T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing, stopping or reversing Alzheimer’s disease. Read More

The release as fetched from its publisher. t3dtherapeutics.com ↗